JP2023155497A - topical skin care compositions - Google Patents
topical skin care compositions Download PDFInfo
- Publication number
- JP2023155497A JP2023155497A JP2023142791A JP2023142791A JP2023155497A JP 2023155497 A JP2023155497 A JP 2023155497A JP 2023142791 A JP2023142791 A JP 2023142791A JP 2023142791 A JP2023142791 A JP 2023142791A JP 2023155497 A JP2023155497 A JP 2023155497A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- skin care
- composition
- vitamin
- care composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title abstract description 135
- 230000000699 topical effect Effects 0.000 title abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- KBHSAMYHDBBRKS-QTJGBDASSA-N 2-hydroxy-n-[(2s,3s,4r)-1,3,4-trihydroxyoctadecan-2-yl]benzamide Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC(=O)C1=CC=CC=C1O KBHSAMYHDBBRKS-QTJGBDASSA-N 0.000 claims abstract description 11
- 235000019864 coconut oil Nutrition 0.000 claims abstract description 11
- 239000003240 coconut oil Substances 0.000 claims abstract description 11
- 229940077859 salicyloyl phytosphingosine Drugs 0.000 claims abstract description 11
- YRWWOAFMPXPHEJ-OFBPEYICSA-K sodium L-ascorbic acid 2-phosphate Chemical compound [Na+].[Na+].[Na+].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1[O-] YRWWOAFMPXPHEJ-OFBPEYICSA-K 0.000 claims abstract description 11
- 229940048058 sodium ascorbyl phosphate Drugs 0.000 claims abstract description 11
- 229920002683 Glycosaminoglycan Polymers 0.000 claims abstract description 10
- POYIQRAKQJCAJV-TXSQEWSBSA-L disodium;3-[2-carboxylatoethyl(dodecyl)amino]propanoate;[(2r)-2,5,7,8-tetramethyl-2-[(4r,8r)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] dihydrogen phosphate Chemical compound [Na+].[Na+].CCCCCCCCCCCCN(CCC([O-])=O)CCC([O-])=O.OP(=O)(O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C POYIQRAKQJCAJV-TXSQEWSBSA-L 0.000 claims abstract description 9
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims abstract description 6
- 235000011399 aloe vera Nutrition 0.000 claims description 12
- 239000006071 cream Substances 0.000 claims description 11
- 244000144927 Aloe barbadensis Species 0.000 claims description 10
- 235000002961 Aloe barbadensis Nutrition 0.000 claims description 10
- 235000013500 Melia azadirachta Nutrition 0.000 claims description 10
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 9
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 9
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 9
- 229920002401 polyacrylamide Polymers 0.000 claims description 8
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 7
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 claims description 7
- 229960005323 phenoxyethanol Drugs 0.000 claims description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 6
- AEIJTFQOBWATKX-UHFFFAOYSA-N octane-1,2-diol Chemical compound CCCCCCC(O)CO AEIJTFQOBWATKX-UHFFFAOYSA-N 0.000 claims description 6
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 6
- 229920002884 Laureth 4 Polymers 0.000 claims description 5
- 241001303601 Rosacea Species 0.000 claims description 5
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 5
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 5
- 229940061515 laureth-4 Drugs 0.000 claims description 5
- 201000004700 rosacea Diseases 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 4
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims description 4
- 240000005343 Azadirachta indica Species 0.000 claims 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical compound [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 claims 1
- 239000004615 ingredient Substances 0.000 abstract description 18
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 abstract description 15
- 238000000034 method Methods 0.000 abstract description 13
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract description 10
- 239000003981 vehicle Substances 0.000 abstract description 10
- 229940088594 vitamin Drugs 0.000 abstract description 9
- 229930003231 vitamin Natural products 0.000 abstract description 9
- 235000013343 vitamin Nutrition 0.000 abstract description 9
- 239000011782 vitamin Substances 0.000 abstract description 9
- 210000000744 eyelid Anatomy 0.000 abstract description 8
- 229930003427 Vitamin E Natural products 0.000 abstract description 7
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 abstract description 7
- 239000003921 oil Substances 0.000 abstract description 7
- 235000019198 oils Nutrition 0.000 abstract description 7
- -1 such as Substances 0.000 abstract description 7
- 239000011709 vitamin E Substances 0.000 abstract description 7
- 235000019165 vitamin E Nutrition 0.000 abstract description 7
- 229940046009 vitamin E Drugs 0.000 abstract description 7
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 abstract description 4
- 229930003268 Vitamin C Natural products 0.000 abstract description 4
- 229940119170 jojoba wax Drugs 0.000 abstract description 4
- 235000019154 vitamin C Nutrition 0.000 abstract description 4
- 239000011718 vitamin C Substances 0.000 abstract description 4
- 244000060011 Cocos nucifera Species 0.000 abstract description 2
- 235000013162 Cocos nucifera Nutrition 0.000 abstract description 2
- 239000001140 aloe barbadensis leaf extract Substances 0.000 abstract description 2
- 150000003700 vitamin C derivatives Chemical class 0.000 abstract description 2
- 150000003626 triacylglycerols Chemical class 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 122
- 206010015150 Erythema Diseases 0.000 description 30
- 244000237986 Melia azadirachta Species 0.000 description 9
- AERBNCYCJBRYDG-UHFFFAOYSA-N D-ribo-phytosphingosine Natural products CCCCCCCCCCCCCCC(O)C(O)C(N)CO AERBNCYCJBRYDG-UHFFFAOYSA-N 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- AERBNCYCJBRYDG-KSZLIROESA-N phytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO AERBNCYCJBRYDG-KSZLIROESA-N 0.000 description 8
- 229940033329 phytosphingosine Drugs 0.000 description 8
- DWHIUNMOTRUVPG-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCO DWHIUNMOTRUVPG-UHFFFAOYSA-N 0.000 description 7
- 229940031674 laureth-7 Drugs 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 6
- 235000004433 Simmondsia californica Nutrition 0.000 description 6
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 241000221095 Simmondsia Species 0.000 description 5
- 206010040880 Skin irritation Diseases 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000004140 cleaning Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000007794 irritation Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000036556 skin irritation Effects 0.000 description 5
- 231100000475 skin irritation Toxicity 0.000 description 5
- 235000002639 sodium chloride Nutrition 0.000 description 5
- 239000002562 thickening agent Substances 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000003750 conditioning effect Effects 0.000 description 4
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 4
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 3
- 241001116389 Aloe Species 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 239000001685 glycyrrhizic acid Substances 0.000 description 3
- 239000003906 humectant Substances 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000037394 skin elasticity Effects 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- OUNZARDETXBPIX-UHFFFAOYSA-N 2-(2-dodecoxyethoxy)acetic acid Chemical compound CCCCCCCCCCCCOCCOCC(O)=O OUNZARDETXBPIX-UHFFFAOYSA-N 0.000 description 2
- MQFYRUGXOJAUQK-UHFFFAOYSA-N 2-[2-[2-(2-octadecanoyloxyethoxy)ethoxy]ethoxy]ethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOCCOCCOCCOC(=O)CCCCCCCCCCCCCCCCC MQFYRUGXOJAUQK-UHFFFAOYSA-N 0.000 description 2
- IXOCGRPBILEGOX-UHFFFAOYSA-N 3-[3-(dodecanoylamino)propyl-dimethylazaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC(O)CS([O-])(=O)=O IXOCGRPBILEGOX-UHFFFAOYSA-N 0.000 description 2
- 241000195940 Bryophyta Species 0.000 description 2
- 241000032203 Conus aureus Species 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- 241000243142 Porifera Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- JUIUXBHZFNHITF-IEOSBIPESA-N [(2r)-2,5,7,8-tetramethyl-2-[(4r,8r)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] dihydrogen phosphate Chemical compound OP(=O)(O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C JUIUXBHZFNHITF-IEOSBIPESA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- QKQCPXJIOJLHAL-UHFFFAOYSA-L disodium;2-[2-(carboxylatomethoxy)ethyl-[2-(dodecanoylamino)ethyl]amino]acetate Chemical compound [Na+].[Na+].CCCCCCCCCCCC(=O)NCCN(CC([O-])=O)CCOCC([O-])=O QKQCPXJIOJLHAL-UHFFFAOYSA-L 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 210000001339 epidermal cell Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 229940071188 lauroamphodiacetate Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 235000011929 mousse Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229940102544 sodium laureth-13 carboxylate Drugs 0.000 description 2
- 229940102541 sodium trideceth sulfate Drugs 0.000 description 2
- KLYDBHUQNXKACI-UHFFFAOYSA-M sodium;2-[2-(2-tridecoxyethoxy)ethoxy]ethyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCOCCOCCOCCOS([O-])(=O)=O KLYDBHUQNXKACI-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 150000003410 sphingosines Chemical class 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000004753 textile Substances 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- 150000003712 vitamin E derivatives Chemical class 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LPLVUJXQOOQHMX-MOGLOQIBSA-N (2s,3s,4s,5r,6r)-6-[(2r,3r,4s,5s,6s)-2-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-6-carboxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-c Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-MOGLOQIBSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 244000303769 Amaranthus cruentus Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920001090 Polyaminopropyl biguanide Polymers 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- 244000044822 Simmondsia californica Species 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- CJPQIRJHIZUAQP-MRXNPFEDSA-N benalaxyl-M Chemical compound CC=1C=CC=C(C)C=1N([C@H](C)C(=O)OC)C(=O)CC1=CC=CC=C1 CJPQIRJHIZUAQP-MRXNPFEDSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- KSDGSKVLUHKDAL-UHFFFAOYSA-L disodium;3-[2-carboxylatoethyl(dodecyl)amino]propanoate Chemical compound [Na+].[Na+].CCCCCCCCCCCCN(CCC([O-])=O)CCC([O-])=O KSDGSKVLUHKDAL-UHFFFAOYSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000001649 glycyrrhiza glabra l. absolute Substances 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000749 insecticidal effect Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 239000002973 irritant agent Substances 0.000 description 1
- 229940051810 licorice root extract Drugs 0.000 description 1
- 235000020725 licorice root extract Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000001069 nematicidal effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003038 phytosphingosines Chemical class 0.000 description 1
- 229940093424 polyaminopropyl biguanide Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000003405 preventing effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002964 rayon Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037393 skin firmness Effects 0.000 description 1
- 230000037067 skin hydration Effects 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 229950006451 sorbitan laurate Drugs 0.000 description 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 150000003611 tocopherol derivatives Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/58—Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8158—Homopolymers or copolymers of amides or imides, e.g. (meth) acrylamide; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
本発明は、一般に、皮膚の発赤を治療するために使用される局所塗布製剤の分野に関する。 The present invention relates generally to the field of topical formulations used to treat skin redness.
皮膚の発赤は一般的な症状である。皮膚の発赤は、酒さ（ｒｏｓａｃｅａ）、皮膚アレルギー、特定のスキンケア製品またはトリートメントの使用、美容処置、運動、および、場合によっては基礎疾患によって引き起こされることがある。例えば、酒さは、顔面に発赤および目に見える血管を生じ、小さな赤い膿の詰まった吹き出物を生じることもある。これらの兆候または症候は、数週間から数か月の期間で突発し、その後しばらくの間軽減する。発赤は必ずしも不安材料ではないかもれないが、この皮膚症状に苦しむ人にとっては、恥ずかしく、腹立たしく、不快である場合がある。 Skin redness is a common symptom. Skin redness can be caused by rosacea, skin allergies, the use of certain skin care products or treatments, cosmetic procedures, exercise, and sometimes underlying medical conditions. For example, rosacea causes redness and visible blood vessels on the face, and may also produce small red, pus-filled pimples. These signs or symptoms come on suddenly over a period of weeks to months and then subside for a period of time. Although redness may not necessarily be cause for alarm, it can be embarrassing, irritating, and uncomfortable for those who suffer from this skin condition.
抗発赤クリームは、刺激を止め、皮膚に潤いを与えるために一般的に使用される。しかしながら、全ての抗発赤クリームが効果的であるわけではないか、または、皮膚の発赤の根本原因を治療できる配合物を含んでいるわけではない。いくつかの抗発赤クリームには、連続して何週間も毎日使用した場合に皮膚が薄くなることを引き起こす可能性のある、ステロイドや他の成分が含まれている。いくつかの保湿剤は、不安定で皮膚刺激を引き起こすか、または、不十分な保湿能力を有する。 Anti-redness creams are commonly used to stop irritation and moisturize the skin. However, not all anti-redness creams are effective or contain formulations that can treat the root cause of skin redness. Some anti-redness creams contain steroids and other ingredients that can cause skin thinning if used daily for many consecutive weeks. Some moisturizers are unstable, cause skin irritation, or have insufficient moisturizing ability.
したがって、皮膚の発赤および皮膚の炎症を軽減する安定な組成物が必要とされている。この組成物はステロイドまたは他の同様の物質を含まないのがよい。この組成物はまた、どんな刺激も他の有害な副作用も引き起こすことなく、皮膚に潤いを与え、穏やかにするのがよい。 Therefore, there is a need for stable compositions that reduce skin redness and skin irritation. The composition should be free of steroids or other similar substances. The composition should also moisturize and soothe the skin without causing any irritation or other harmful side effects.
一実施形態によると、本発明は、水などの皮膚科学的に許容可能なビヒクルと、そのビヒクルに溶解している複数の成分とを有する局所スキンケア組成物である。前記複数の成分は、天然油配合物；複数のビタミン；および０．１－１ｗｔ％サリチロイルフィトスフィンゴシンを含む。前記組成物は、まぶたまたは目領域への塗布には適さない。前記天然油配合物は、アロエベラ葉液汁抽出物；ココヤシ（ココナッツオイル）；加水分解グリコサミノグリカン；およびトリ（カプリル酸／カプリン酸）グリセリルを含む。前記複数のビタミンは、ビタミンＣ、ビタミンＥ、ビタミンＣの塩／誘導体、ビタミンＥの塩／誘導体、およびそれらの混合物からなる群から選択される。一態様において、前記複数のビタミンは、アスコルビルリン酸ナトリウム；ラウリミノジプロピオン酸トコフェリルリン酸二ナトリウム；およびホホバ油を含む。前記複数の成分はさらに、（Ａ）乾燥ニーム葉抽出物（メリアアザジラクタ）；および（Ｂ）アセチル化テトラペプチドを備える。前記複数の成分は、さらに増粘剤を含む。前記増粘剤は、ポリアクリルアミド、Ｃ１３－１４イソパラフィン、ラウレス－７およびそれらの混合物からなる群から選択される。前記複数の成分は、さらに、以下の塩を含む：（Ａ）ヒアルロン酸；および（Ｂ）グリチルリチン酸。 According to one embodiment, the invention is a topical skin care composition having a dermatologically acceptable vehicle, such as water, and a plurality of ingredients dissolved in the vehicle. The ingredients include a natural oil formulation; vitamins; and 0.1-1 wt% salicyloyl phytosphingosine. Said composition is not suitable for application to the eyelids or eye area. The natural oil formulation includes aloe vera leaf sap extract; coconut oil; hydrolyzed glycosaminoglycans; and caprylic/capric triglyceride. The plurality of vitamins are selected from the group consisting of vitamin C, vitamin E, salts/derivatives of vitamin C, salts/derivatives of vitamin E, and mixtures thereof. In one embodiment, the plurality of vitamins includes sodium ascorbyl phosphate; disodium tocopheryl lauriminodipropionate phosphate; and jojoba oil. The plurality of components further include (A) dried neem leaf extract (Melia azadirachta); and (B) acetylated tetrapeptide. The plurality of components further include a thickener. The thickener is selected from the group consisting of polyacrylamide, C13-14 isoparaffin, laureth-7 and mixtures thereof. The plurality of components further include the following salts: (A) hyaluronic acid; and (B) glycyrrhizic acid.
一態様において、局所スキンケア組成物は、噴霧乾燥粉末アロエベラ；ココヤシ（ココナッツオイル）；乾燥ニーム葉抽出物（メリアアザジラクタ）；アセチルテトラペプチド－４０；ヒアルロン酸ナトリウム；グリチルリチン酸二カリウム；約０．２ｗｔ％サリチロイルフィトスフィンゴシン；アスコルビルリン酸ナトリウム；および水を含む。前記組成物はさらに、ポリアクリルアミド、Ｃ１３－１４イソパラフィン、ラウレス－７およびそれらの混合物からなる群から選択される増粘剤を含む。前記組成物はさらに、加水分解グリコサミノグリカンを含む。前記組成物は、ラウリミノジプロピオン酸トコフェリルリン酸二ナトリウムを含む。 In one embodiment, the topical skin care composition comprises spray-dried powdered aloe vera; coco coir (coconut oil); dried neem leaf extract (Melia azadirachta); acetyl tetrapeptide-40; sodium hyaluronate; dipotassium glycyrrhizinate; about 0 .2 wt% salicyloyl phytosphingosine; sodium ascorbyl phosphate; and water. The composition further comprises a thickening agent selected from the group consisting of polyacrylamide, C13-14 isoparaffin, laureth-7 and mixtures thereof. The composition further includes hydrolyzed glycosaminoglycans. The composition includes disodium lauriminodipropionate tocopheryl phosphate.
組成物は、ローション、クリーム、セラム、ジェル、スティック、スプレー、軟膏、液体洗浄液、泡（ｆｏａｍ）、およびムースからなる群から選択される形態である。組成物は２５℃において、３０，０００－５０，０００ｃＰｓの粘度を有する。組成物は、４．５－６．０の間のｐＨを有する。 The composition is in a form selected from the group consisting of lotions, creams, serums, gels, sticks, sprays, ointments, liquid washes, foams, and mousses. The composition has a viscosity of 30,000-50,000 cPs at 25°C. The composition has a pH between 4.5-6.0.
別の実施形態において、皮膚発赤を有する人を治療するための方法であって、本明細書に記載した局所スキンケア組成物の有効量を投与すること；および前記組成物を皮膚に留まらせておくことを含む。ある実施形態において、スキンケア組成物は、すすぐ必要なしに製剤の残りとして皮膚に留まらせておくことができる。前記組成物は、皮膚の発赤の軽減を引き起こすように６０日間投与され得る。一態様において、本方法はさらに、前記局所スキンケア組成物の投与の前に、毛穴を詰まらせない組成物で肌を予備洗浄することをさらに含む。 In another embodiment, a method for treating a person with skin redness, comprising: administering an effective amount of a topical skin care composition described herein; and allowing said composition to remain on the skin. Including. In some embodiments, the skin care composition can be left on the skin as a residual formulation without the need for rinsing. The composition may be administered for 60 days to cause a reduction in skin redness. In one embodiment, the method further comprises pre-cleansing the skin with a non-pore-clogging composition prior to administering the topical skin care composition.
さらに別の実施形態において、本発明は、（Ａ）抗発赤組成物を収容している第１の容器であって、前記抗発赤組成物は、約７－１２重量％（ｗｔ％）のアロエベラ葉液汁抽出物；約３－９ｗｔ％のココヤシ（ココナッツオイル）；約１－４ｗｔ％ビタミンＥおよび／またはビタミンＥの誘導体；および約０．１－１ｗｔ％サリチロイルフィトスフィンゴシン；を含む前記第１の容器と、（Ｂ）第２組成物を収容している第２の容器であって、前記第２組成物は、毛穴を詰まらせないクレンザーであり、前記クレンザーは、ラウリン酸ＰＥＧ－８０ソルビタン；トリデセス硫酸ナトリウム；コカミドプロピルヒドロキシスルタイン；ジステアリン酸ＰＥＧ－１５０；ラウロアンホ二酢酸ナトリウム；ラウレス－１３カルボン酸ナトリウム；およびＰＥＧ－１５ココポリアミンを含む、前記第２の容器とを備えるキットである。 In yet another embodiment, the present invention provides a first container containing (A) an anti-redness composition, wherein the anti-redness composition comprises about 7-12 weight percent (wt%) aloe vera. Leaf sap extract; about 3-9 wt% coconut oil; about 1-4 wt% vitamin E and/or derivatives of vitamin E; and about 0.1-1 wt% salicyloyl phytosphingosine; (B) a second container containing a second composition, the second composition being a pore-clogging cleanser, and the cleanser containing PEG-80 lauric acid; sorbitan; sodium trideceth sulfate; cocamidopropyl hydroxysultaine; PEG-150 distearate; sodium lauroamphodiacetate; sodium laureth-13 carboxylate; and the second container comprising PEG-15 cocopolyamine. be.
用語および熟語「発明」、「本発明」、「本願発明」および同様の用語および熟語は、本明細書に使用されるとき、非限定的であり、本主題を任意の単一の実施形態に限定することは意図されておらず、むしろ、記載されたすべての可能な実施形態を包含する。 The terms and phrases "invention," "this invention," "invention" and similar terms and phrases, when used herein, are non-limiting and do not limit the subject matter to any single embodiment. It is not intended to be limiting, but rather includes all possible embodiments described.
本明細書に使用されるとき、すべての重量パーセント（ｗｔ％）は、特に明記しない限り、スキンケア組成物の総ｗｔ％に基づく。加えて、全ての組成物の割合は、特に明記しない限り、１００ｗｔ％に等しい合計に基づく。 As used herein, all weight percentages (wt%) are based on the total wt% of the skin care composition, unless otherwise specified. In addition, all composition percentages are based on a total equal to 100 wt% unless otherwise specified.
組成物およびそれらの使用方法は、本明細書を通して開示される成分または工程のうちの任意のものを「備える（ｃｏｍｐｒｉｓｅ）」ことができ、または当該任意のもの「から本質的になる（ｃｏｎｓｉｓｔ ｅｓｓｅｎｔｉａｌｌｙ ｏｆ）」または「からなる（ｃｏｎｓｉｓｔ ｏｆ）」ことができる。本明細書および特許請求の範囲で使用されるとき、単語「備える（ｃｏｍｐｒｉｓｉｎｇ）」（およびその任意の変形語）、「有する（ｈａｖｉｎｇ）」（およびその任意の変形語）、「含む（ｉｎｃｌｕｄｉｎｇ）」（およびその任意の変形語）、または「収容する（ｃｏｎｔａｉｎｉｎｇ）」（およびその任意の変形語）は、包括的または非限定（ｏｐｅｎ－ｅｎｄｅｄ）であり、本発明の成分を含むことができ、本明細書に記載される他の成分または要素を除外しない。特許請求の範囲および／または明細書において、用語「備える（ｃｏｍｐｒｉｓｉｎｇ）」と組み合わせて使用されるとき、単語「１つの（“ａ”、“ａｎ”）」の使用は、「１つ」を意味する場合があるが、「１つ以上」「少なくとも１つ」および「１つまたは１つより多い」の意味とも一致する。本明細書に使用されるとき、「から本質的になる」とは、本発明が請求項に記載されたものに加えて追加の成分を含む場合があることを意味する（ただし、追加の成分が特許請求する発明の基本的かつ新規な特徴を実質的に変更しない場合に限る）。一般に、そのような追加の成分は、まったく存在しないか、微量でのみ存在する場合がある。しかしながら、（有用性の程度とは対照的に）組成物の有用性が維持される限り、本発明の基本的かつ新規な特徴を実質的に変更し得る材料を重量の約１０％まで含むことがありうる。 Compositions and methods of using them can "comprise" or "consist essentially of" any of the ingredients or steps disclosed throughout this specification. can be "of" or "consist of". As used in this specification and the claims, the words "comprising" (and any variations thereof), "having" (and any variations thereof), "including" ” (and any variations thereof), or “containing” (and any variations thereof) are inclusive or open-ended and may include components of the present invention. , does not exclude other components or elements described herein. In the claims and/or specification, when used in combination with the term “comprising,” the use of the word “a” or “an” means “a.” However, it is also consistent with the meanings of "one or more," "at least one," and "one or more than one." As used herein, "consisting essentially of" means that the invention may include additional ingredients in addition to those recited in the claims (provided that additional ingredients does not substantially change the essential and novel features of the claimed invention). Generally, such additional ingredients may be absent at all or present only in trace amounts. However, as long as the usefulness (as opposed to the degree of usefulness) of the composition is maintained, it may contain up to about 10% by weight of materials that may materially alter the basic and novel features of the invention. is possible.
本明細書に記載されるすべての範囲は、２つの値の「間の」範囲を記載するものを含め、両端点を含む。「約」、「一般的に」、「実質的（ｓｕｂｓｔａｎｔｉａｌｌｙ）」などの用語は、それが絶対的ではないように用語または値を変更するものとして解釈されたい。そのような用語は、それらの用語が当業者によって理解されるようにそれらが変更する状況および用語によって定義されるであろう。非限定的な一実施形態において、それら用語は５％以内、より好ましくは１％以内、最も好ましくは０．５％以内であると定義される。用語「実質的」およびその変形は、当業者によって理解されるように明記されているものの大部分ではあるが必ずしも全面的にそうではないものとして定義され、非限定的な一実施形態において、実質的は０．５％－５％の範囲内を表す。 All ranges stated herein, including those reciting ranges “between” two values, are inclusive of the endpoints. Terms such as "about," "generally," "substantially," and the like should be construed as modifying the term or value so that it is not absolute. Such terms will be defined by the changing context and terminology as they are understood by those skilled in the art. In one non-limiting embodiment, the terms are defined to be within 5%, more preferably within 1%, and most preferably within 0.5%. The term "substantial" and variations thereof are defined to mean most, but not necessarily all, of what is specified as understood by those skilled in the art, and in one non-limiting embodiment, substantially The target is within the range of 0.5%-5%.
本明細書に使用されるとき、組成物の「有効量」という用語は、所望の生物学的応答を誘発するのに十分な量を指す。当業者によって理解されるように、物質の有効量は、所望の生物学的エンドポイントや患者などのような要因に応じて異なりうる。いくつかの実施形態において、組成物の治療有効量は、疾患、病気、および／または症状に苦しんでいるまたは罹患しやすい対象に投与されるとき、皮膚の発赤および皮膚炎症の１つ以上の症候の治療、抑制、軽減、防止、および／または遅延に十分な量である。用語「治療する」または「軽減する」またはこれらの用語の任意の変形には、皮膚の発赤の測定可能な減少が含まれる。例えば、皮膚発赤を治療するための組成物の有効量／治療有効量は、皮膚発赤と炎症に関連する１つ以上の症候または特徴の発生を低減、改善、緩和、抑制、防止、発症の遅延、重症度の低減、および／または発生率の低減する量である。 As used herein, the term "effective amount" of a composition refers to an amount sufficient to elicit a desired biological response. As will be understood by those skilled in the art, the effective amount of a substance may vary depending on factors such as the desired biological endpoint, the patient, and the like. In some embodiments, a therapeutically effective amount of the composition, when administered to a subject suffering from or susceptible to a disease, disease, and/or condition, reduces one or more symptoms of skin redness and skin irritation. in an amount sufficient to treat, inhibit, reduce, prevent, and/or delay. The terms "treat" or "alleviate" or any variations of these terms include a measurable reduction in skin redness. For example, an effective amount/therapeutically effective amount of a composition for treating skin redness may reduce, ameliorate, alleviate, suppress, prevent, delay the onset of, one or more symptoms or characteristics associated with skin redness and inflammation. , a reduction in severity, and/or an amount that reduces incidence.
スキンケア製品は健康的で魅力的な皮膚を得るために使用される。本発明は、サリチロイルフィトスフィンゴシン、天然油およびビタミンを含有する局所スキンケア組成物を提供する。本組成物は、発赤、皮膚の斑点状／しみ状の外観および炎症を効果的に軽減／改善することができる。本組成物は、皮膚の弾力性などの皮膚のきめの改善を促進し、柔軟性を回復させ、剥離を低減し、それにより老化の兆候を最小限に抑えることができる。スキンケア組成物の特定の実施形態は、抗菌性および抗真菌性を含む抗炎症特性を有する。本組成物は、皮膚の自然なバランスを維持するように皮膚の保湿をさらに促進する。 Skin care products are used to obtain healthy and attractive skin. The present invention provides topical skin care compositions containing salicyloylphytosphingosine, natural oils, and vitamins. The composition can effectively reduce/improve redness, patchy/spotty appearance of the skin and inflammation. The composition can promote improvement of skin texture, such as skin elasticity, restore suppleness, and reduce flaking, thereby minimizing signs of aging. Certain embodiments of skin care compositions have anti-inflammatory properties, including antibacterial and antifungal properties. The composition further promotes skin hydration to maintain the skin's natural balance.
本明細書に使用されるとき、用語「スキンケア組成物」「製品」「組成物」および複数形の用語を含む同様の単語は、互換的に使用できる。具体的には、用語スキンケア組成物は、皮膚の発赤を軽減するために、皮膚またはその任意の部分に擦り込まれ、広げられ、導入され、またはその他塗布され得る組成物を含む。用語「スキンケア組成物」および他の用語は、具体的にはヒトの皮膚に塗布するための局所用組成物が含まれる。用語「局所塗布」は、スキンケア組成物を皮膚の表面に塗布することを意味する。 As used herein, the terms "skin care composition," "product," "composition," and similar words, including plural terms, may be used interchangeably. Specifically, the term skin care composition includes compositions that can be rubbed, spread, introduced, or otherwise applied to the skin or any part thereof to reduce redness of the skin. The term "skin care composition" and other terms specifically include topical compositions for application to human skin. The term "topical application" means applying a skin care composition to the surface of the skin.
本発明は、従来技術では十分に取り組まれていなかった課題に取り組み、従来技術とは異なるその課題に対する解決策を提供する。各成分（およびその割合）は、皮膚の発赤および刺激を治療するために慎重に選択されている。実施形態のうちのいくつかは、特に、大腸菌（Ｅ．ｃｏｌｉ）、緑膿菌（Ｐ．ａｅｒｕｇｉｎｏｓａ）、黄色ブドウ球菌（Ｓ．ａｕｒｅｕｓ）、Ｃ．アルビカンス（Ｃ．ａｌｂｉｃａｎｓ）、Ａ．ブラジリエンシス（Ａ．ｂｒａｓｉｌｉｅｎｓｉｓ）および他の微生物などの１つ以上の微生物によって引き起こされる皮膚症状を治療する。スキンケア組成物は、酒さ、アレルギー反応、過剰な免疫反応および美容処置による皮膚の発赤および炎症を軽減するために使用され得る。好ましくは、本発明のスキンケア組成物は、皮膚に通常の量を塗布した後、目に見える残留物または際立った粘着性を残すことなく、迅速かつきれいに乾燥するように作られる。スキンケア組成物は安定しており、皮膚に塗布した場合、過度の毒性、不適合、またはアレルギー反応を回避するように作られる。本発明の局所スキンケア組成物は、皮膚への塗布後に際立った滴りまたは溜まりを回避するように選択された粘度を有することができる。 The present invention addresses a problem that has not been adequately addressed by the prior art and provides a different solution to that problem than the prior art. Each ingredient (and its proportions) has been carefully selected to treat skin redness and irritation. Some of the embodiments include, among others, E. coli, P. aeruginosa, S. aureus, C. aureus, and C. aureus. C. albicans, A. skin conditions caused by one or more microorganisms, such as A. brasiliensis and other microorganisms. Skin care compositions can be used to reduce skin redness and inflammation due to rosacea, allergic reactions, excessive immune responses, and cosmetic procedures. Preferably, the skin care compositions of the present invention are made to dry quickly and cleanly after application of a normal amount to the skin, without leaving any visible residue or noticeable stickiness. Skin care compositions are stable and designed to avoid undue toxicity, incompatibility, or allergic reactions when applied to the skin. The topical skin care compositions of the present invention can have a viscosity selected to avoid significant dripping or pooling after application to the skin.
有利には、スキンケア組成物は、皮膚科学的に許容可能なビヒクルと、そのビヒクルに溶解した１つ以上の成分とを含む。その成分は、選択されたビヒクルに対して混和性（ｃｏｍｐａｔｉｂｌｅ）を有しており、その選択されたビヒクル中で安定であるように選択される。一実施形態において、ビヒクルは水を含む。水は蒸留水でも脱イオン水であり得る。しかしながら、アルコールまたはプロピレングリコールなどの他の適切なビヒクルもまた使用することができる。溶解される成分には、天然油配合物、複数のビタミン、およびスフィンゴイド脂質が含まれる。 Advantageously, the skin care composition comprises a dermatologically acceptable vehicle and one or more ingredients dissolved in the vehicle. The components are selected to be compatible with and stable in the selected vehicle. In one embodiment, the vehicle includes water. The water can be distilled or deionized. However, other suitable vehicles such as alcohol or propylene glycol can also be used. Ingredients that are dissolved include natural oil formulations, multiple vitamins, and sphingoid lipids.
天然油または保湿剤には、アロエベラ葉液汁（ａｌｏｅ ｂａｒｂａｄｅｎｓｉｓ ｌｅａｆ ｊｕｉｃｅ）またはアロエベラ、ココヤシ（ｃｏｃｏｓ ｎｕｃｉｆｅｒａ）（ココナッツオイル）、グリコサミノグリカン、加水分解グリコサミノグリカンおよびトリ（カプリル酸／カプリン酸）グリセリルが含まれるが、これらに限定されない。アロエベラは、剥離の低減および柔軟性の回復によって、乾燥した肌または傷ついた肌の外観を向上させる。アロエは概してアロエ植物の葉から得られる。アロエは、傷の治癒と皮膚の炎症を改善する。ココヤシ（ココナッツ）オイルは、皮膚の弾力性を促進する皮膚コンディショニング剤である。加水分解グリコサミノグリカンは、保湿剤およびコンディショニング剤として機能する。加水分解グリコサミノグリカンは水と効率的に結合し、深部水分補給を増加させ、皮膚の弾力性とハリを改善する。トリ（カプリル酸／カプリン酸）グリセリルは、ココナッツオイルに由来する皮膚コンディショニング剤である。 Natural oils or humectants include aloe barbadensis leaf juice or aloe vera, cocos nucifera (coconut oil), glycosaminoglycans, hydrolyzed glycosaminoglycans and tri(caprylic/capric acid) Including, but not limited to, glyceryl. Aloe vera improves the appearance of dry or damaged skin by reducing flaking and restoring suppleness. Aloe is generally obtained from the leaves of the aloe plant. Aloe improves wound healing and skin inflammation. Coconut oil is a skin conditioning agent that promotes skin elasticity. Hydrolyzed glycosaminoglycans function as humectants and conditioning agents. Hydrolyzed glycosaminoglycans efficiently bind water, increasing deep hydration and improving skin elasticity and firmness. Caprylic/capric triglyceride is a skin conditioning agent derived from coconut oil.
スキンケア組成物は、さらに１つ以上のビタミンまたはビタミン誘導体を含む。例えば、組成物は、アスコルビン酸またはその塩、リン酸トコフェリルまたは酢酸トコフェリルおよびシモンジア・キネンシス（Ｓｉｍｍｏｎｄｓｉａ Ｃｈｉｎｅｎｓｉｓ）（ホホバ）種子油などのビタミンＣおよびビタミンＥの供給源を含み得る。一実施形態において、スキンケア組成物は、アスコルビルリン酸ナトリウム、ラウリミノジプロピオン酸トコフェリルリン酸二ナトリウム（ＤＬＴＰ）、ホホバ油を含む。アスコルビルリン酸ナトリウムは、コラーゲンの生成、組織の修復、および神経伝達物質の合成に必要な必須栄養素であるビタミンＣを提供する。ＤＬＴＰはビタミンＥから単離される。ＤＬＴＰは、にきび治療、傷跡治療、酒さ治療、および保湿剤として、コンディショナー成分として、日焼け止め成分として使用され、およびアンチエイジングのために使用される。ＤＬＴＰ。炎症を起こした部位に塗布すると、皮膚の発赤および炎症の減少を効果的に促進でき、皮膚の炎症を軽減できる。ホホバ種子油は皮膚コンディショニング剤または皮膚軟化剤である。ホホバ種子油は、抗菌性があり、ビタミンＥが含まれている。 The skin care composition further includes one or more vitamins or vitamin derivatives. For example, the composition may include a source of vitamin C and vitamin E, such as ascorbic acid or a salt thereof, tocopheryl phosphate or acetate, and Simmondsia chinensis (jojoba) seed oil. In one embodiment, the skin care composition includes sodium ascorbyl phosphate, disodium lauriminodipropionate tocopheryl phosphate (DLTP), and jojoba oil. Sodium ascorbyl phosphate provides vitamin C, an essential nutrient needed for collagen production, tissue repair, and neurotransmitter synthesis. DLTP is isolated from vitamin E. DLTP is used in acne treatment, scar treatment, rosacea treatment, and as a moisturizer, as a conditioner ingredient, as a sunscreen ingredient, and for anti-aging. DLTP. When applied to inflamed areas, it can effectively promote the reduction of skin redness and inflammation, and can reduce skin inflammation. Jojoba seed oil is a skin conditioning agent or emollient. Jojoba seed oil is antibacterial and contains vitamin E.
スフィンゴイド脂質は、フィトスフィンゴシン（ＰＳＧ）またはその誘導体などの抗菌剤、抗炎症剤、および抗刺激剤を備える。用語「抗刺激（ａｎｔｉ－ｉｒｒｉｔａｎｔ）」は、本明細書に使用されるとき、皮膚などの身体部分の痛み、荒れ、または炎症を防止または軽減する薬剤である。ＰＳＧは、１日を通して保湿力を高めるために、外表皮の天然脂質層を模倣する水結合剤である。ＰＳＧは抗発赤および皮膚の引き締め性があり、微生物を抑制することができる。有益なことに、ＰＳＧは抗菌性および傷の治癒性の両方を有し、０．１％という低濃度で抗炎症剤として機能する。ある特定の態様においては、スキンケア組成物は、サリチル酸およびその誘導体でエステル化されたＰＳＧを含む。 Sphingoid lipids include antibacterial, anti-inflammatory, and anti-irritant agents such as phytosphingosine (PSG) or its derivatives. The term "anti-irritant" as used herein is an agent that prevents or reduces pain, irritation, or inflammation in a body part, such as the skin. PSG is a water binding agent that mimics the natural lipid layer of the outer epidermis to enhance hydration throughout the day. PSG has anti-redness and skin tightening properties and can inhibit microorganisms. Beneficially, PSG has both antibacterial and wound healing properties and functions as an anti-inflammatory agent at concentrations as low as 0.1%. In certain embodiments, the skin care composition comprises PSG esterified with salicylic acid and its derivatives.
サリチロイルＰＳＧ（Ｓａｌｉｃｙｌｏｙｌ ＰＳＧ）は、サリチル酸と共有結合している、天然起源の、皮膚と同一のＰＳＧの誘導体である。サリチロイルＰＳＧおよびその誘導体は、皮膚の修復および皮膚の再生、皮膚からの水分の損失の防止、表皮細胞の成長を制御し、表皮細胞の分化のサポートおよびアポトーシスによって老化の兆候を最小限に抑えること、コラーゲン合成を促進し、その分解を低減することによって、成熟または光老化した真皮の状態を改善すること、真皮－表皮接合部を強化すること、および炎症を起こした皮膚を落ち着かせることに寄与する。 Salicyloyl PSG is a naturally occurring, skin-identical derivative of PSG that is covalently bound to salicylic acid. Salicyroyl PSG and its derivatives are effective in skin repair and skin regeneration, preventing water loss from the skin, controlling epidermal cell growth, supporting epidermal cell differentiation and minimizing signs of aging through apoptosis. , contributes to improving the condition of mature or photoaged dermis by promoting collagen synthesis and reducing its degradation, strengthening the dermal-epidermal junction and calming irritated skin. do.
スキンケア組成物は、有利には、メリアアザジラクタ葉抽出物、ヒアルロン酸またはその塩、グリチルリチンまたはグリチルリチン酸またはグリチルリジン酸またはその塩、トコフェロールおよびトコフェロールエステルなどの他の成分を含むことができるが、これらに限定されない。 The skin care composition may advantageously contain other ingredients such as Melia azadirachta leaf extract, hyaluronic acid or its salts, glycyrrhizin or glycyrrhizic acid or glycyrrhizic acid or its salts, tocopherols and tocopherol esters, but Not limited to these.
メリアアザジラクタ（ニーム葉）抽出物には、殺虫性、殺線虫性、殺真菌性、殺菌性、抗炎症性、抗腫瘍性、収斂性、および他の有益な特性がある。
一実施形態において、スキンケア組成物はヒアルロン酸ナトリウムを含む。ヒアルロン酸ナトリウムは、水分を回復させることによりおよび摩擦またはすりむきの防止を補助することにより、皮膚の潤滑剤として機能する。結合組織の細胞外基質に広く分布しているのは、多糖類である。ヒアルロン酸ナトリウムは、他のどの天然物質よりも多くの水を保持でき、例えばその重量の１０００倍までの水を保持できる。ヒアルロン酸ナトリウムは、真皮の深くに到達でき、水と結合し、保水し、水を引き付ける。また、皮膚／血液の微小循環および栄養吸収を促進する。ヒアルロン酸ナトリウムは、その特大の水和性のおかげで、より滑らかで、しわの減少したより柔らかな肌、および、全般的によりふっくらとした外観を促進することができる。
Melia azadirachta (neem leaf) extract has insecticidal, nematicidal, fungicidal, bactericidal, anti-inflammatory, antitumor, astringent, and other beneficial properties.
In one embodiment, the skin care composition includes sodium hyaluronate. Sodium hyaluronate acts as a lubricant for the skin by restoring moisture and helping prevent chafing or chafing. Widely distributed in the extracellular matrix of connective tissue are polysaccharides. Sodium hyaluronate can hold more water than any other natural substance, for example up to 1000 times its weight. Sodium hyaluronate can reach deep into the dermis, bind water, retain water, and attract water. It also promotes skin/blood microcirculation and nutrient absorption. Thanks to its extra hydrating properties, sodium hyaluronate can promote smoother, softer skin with fewer wrinkles, and an overall more plump appearance.
一実施形態において、スキンケア組成物はグリチルリジン酸二カリウムすなわちグリチルリチン酸二カリウム（甘草の根の抽出物）を含む。剥離を低減し、柔軟性を回復させることにより、乾燥または損傷した皮膚の外観を向上させることができる。 In one embodiment, the skin care composition comprises dipotassium glycyrrhizinate or dipotassium glycyrrhizinate (licorice root extract). It can improve the appearance of dry or damaged skin by reducing peeling and restoring suppleness.
一実施形態において、スキンケア組成物はアセチルテトラペプチド－４０などのアセチル化トコフェロールを含む。これは、肌への刺激を軽減し、過剰な免疫反応または炎症によって引き起こされた顔面の発赤の発生を減少させる。 In one embodiment, the skin care composition comprises an acetylated tocopherol, such as acetyltetrapeptide-40. This reduces skin irritation and reduces the occurrence of facial redness caused by excessive immune response or inflammation.
スキンケア組成物は、さらに、１つ以上の増粘剤を含み得る。例えば、ポリアクリルアミド、Ｃ１３－１４イソパラフィン、ラウレス－７およびそれらの混合物を含むことができるが、これらに限定されない。ポリアクリルアミドはさらに成分を結合し、特定の製品を皮膚に保持するように機能する。Ｃ１３－１４イソパラフィンは、また、他の成分の溶媒としても働き得る。ラウレス－７は、界面活性剤／乳化剤として機能することができる。 Skin care compositions may further include one or more thickening agents. Examples include, but are not limited to, polyacrylamide, C13-14 isoparaffin, laureth-7, and mixtures thereof. Polyacrylamide also functions to bind ingredients and hold certain products on the skin. C13-14 isoparaffins can also serve as solvents for other components. Laureth-7 can function as a surfactant/emulsifier.
スキンケア組成物はカプリリルグリコール、ブチレングリコール、ラウレス－４、およびフェノキシエタノールなどの他の成分を含むこともできる。カプリリルグリコールは、防腐剤として機能する抗菌活性のある皮膚軟化剤である。ブチレングリコールは、また、ビヒクルおよび粘度低下剤としても機能できる。ラウレス－４は界面活性剤のクレンジングおよび可溶化剤として機能する。フェノキシエタノールは防腐剤である。 Skin care compositions can also include other ingredients such as caprylyl glycol, butylene glycol, laureth-4, and phenoxyethanol. Caprylyl glycol is an emollient with antimicrobial activity that functions as a preservative. Butylene glycol can also function as a vehicle and viscosity reducing agent. Laureth-4 functions as a surfactant cleansing and solubilizing agent. Phenoxyethanol is a preservative.
特定の一実施形態では、組成物は、水、アロエベラ葉液汁；ココヤシ（ココナッツ）オイル；加水分解グリコサミノグリカン；トリ（カプリル酸／カプリン酸）グリセリル；メリアアザジラクタ葉抽出物；ポリアクリルアミド；Ｃ１３－１４イソパラフィン；ラウレス－７；ラウリミノジプロピオン酸トコフェリルリン酸二ナトリウム；アセチルテトラペプチド－４０；カプリリルグリコール；ブチレングリコール；ヒアルロン酸ナトリウム；シモンジア・キネンシス（ホホバ）種子油；ラウレス－４；サリチロイルフィトスフィンゴシン；グリチルリチン酸二カリウム；アスコルビルリン酸ナトリウム；およびフェノキシエタノールを含む。 In one particular embodiment, the composition comprises water, aloe vera leaf sap; coconut oil; hydrolyzed glycosaminoglycans; caprylic/capric triglyceride; Melia azadirachta leaf extract; polyacrylamide ; C13-14 isoparaffin; Laureth-7; Disodium lauriminodipropionate tocopheryl phosphate; Acetyl tetrapeptide-40; Caprylyl glycol; Butylene glycol; Sodium hyaluronate; Simondia chinensis (jojoba) seed oil; Laureth- 4; salicyloylphytosphingosine; dipotassium glycyrrhizinate; sodium ascorbyl phosphate; and phenoxyethanol.
一実施形態において、組成物は、約５０－７０ｗｔ％蒸留水、約７－１２ｗｔ％アロエベラ葉液汁抽出物および、好ましくは、噴霧乾燥アロエベラ粉末；約３－９ｗｔ％ココヤシ（ココナッツ）オイル；約０．１－１ｗｔ％の好ましくは約０．２ｗｔ％サリチロイルフィトスフィンゴシン；約２－７ｗｔ％加水分解グリコサミノグリカン；約２－７ｗｔ％トリ（カプリル酸／カプリン酸）グリセリルおよびメリアアザジラクタ葉抽出物；約２－７ｗｔ％ポリアクリルアミド、Ｃ１３－１４イソパラフィンおよびラウレス－７；約１－５ｗｔ％ラウリミノジプロピオン酸トコフェリルリン酸二ナトリウム；約１－３ｗｔ％アセチルテトラペプチド－４０およびカプリリルグリコール；約１－３ｗｔ％ブチレングリコール；約０．１－３ｗｔ％ヒアルロン酸ナトリウム；約０．１－３ｗｔ％シモンジア・キネンシス（ホホバ）種子油；約０．１－３ｗｔ％ラウレス－４；約０．１－３ｗｔ％グリチルリチン酸二カリウム；約０．０１－１ｗｔ％アスコルビルリン酸ナトリウム；約０．１－３ｗｔ％フェノキシエタノールおよび０．１－１ｗｔ％カプリリルグリコールを含む。 In one embodiment, the composition comprises about 50-70 wt% distilled water, about 7-12 wt% aloe vera leaf sap extract and, preferably, spray-dried aloe vera powder; about 3-9 wt% coconut oil; .1-1 wt% preferably about 0.2 wt% salicyloylphytosphingosine; about 2-7 wt% hydrolyzed glycosaminoglycans; about 2-7 wt% tri(caprylic/capric)glyceryl and melia azadirachta. Leaf extract; about 2-7 wt% polyacrylamide, C13-14 isoparaffin and laureth-7; about 1-5 wt% tocopheryl phosphate disodium lauriminodipropionate; about 1-3 wt% acetyltetrapeptide-40 and capri Ryl glycol; about 1-3 wt% butylene glycol; about 0.1-3 wt% sodium hyaluronate; about 0.1-3 wt% Simondia chinensis (jojoba) seed oil; about 0.1-3 wt% laureth-4; Contains 0.1-3 wt% dipotassium glycyrrhizinate; about 0.01-1 wt% sodium ascorbyl phosphate; about 0.1-3 wt% phenoxyethanol and 0.1-1 wt% caprylyl glycol.
非限定的な一実施形態において、スキンケア組成物は不透明な白色から灰色がかった白色の粘性のあるローションで、特有の匂いがする。スキンケア組成物は２５℃において４．５－５．５の間のｐＨ範囲を有する。好ましくは、スキンケア組成物は５．００と６．００との間のｐＨを有する。ある実施形態において、スキンケア組成物は５．６５のｐＨを有する。スキンケア組成物は２５℃において、３０，０００－５０，００ｃＰｓの粘度を有し得る（Ｂｒｏｏｋｆｉｅｌｄ ＬＶＴ；スピンドルＴＥで６ｒｐｍ）。好ましくは、スキンケア組成物は３０，０００－４０，０００ｃＰｓの粘度を有する。スキンケア組成物の比重は０．８０００－１．１００である。好ましくは、スキンケア組成物の比重は０．９９０－１．０００である。 In one non-limiting embodiment, the skin care composition is an opaque white to off-white viscous lotion with a distinctive odor. The skin care composition has a pH range between 4.5-5.5 at 25°C. Preferably, the skin care composition has a pH between 5.00 and 6.00. In certain embodiments, the skin care composition has a pH of 5.65. The skin care composition may have a viscosity of 30,000-50,00 cPs at 25° C. (Brookfield LVT; 6 rpm on spindle TE). Preferably, the skin care composition has a viscosity of 30,000-40,000 cPs. The specific gravity of the skin care composition is 0.8000-1.100. Preferably, the skin care composition has a specific gravity of 0.990-1.000.
スキンケア組成物は安定であり、皮膚発赤を治療するために皮膚に塗布した場合、刺激がまったくないか、わずかの刺激（すなわち、全くない、またはほんのわずかの許容できる皮膚刺激性）を引き起こし得る。スキンケア組成物は、ほとんどの皮膚発赤症状の根源だけでなくその結果として生じる症状を治療するためにも使用され得、それにより患者コンプライアンスの改善につながる。また、症候を長期間緩和するための抗炎症性もまた付加されている。本発明の組成物に適用されるとき、用語「安定な」は、通常の周囲空気および光条件下（すなわち、家の居間に通常存在する空気および光の条件）室温（約２５℃）で少なくとも１か月間保存された場合、スキンケア組成物が平らで不活性な表面上に置かれたときに（すなわちその容器から取り除かれたときに）同等の色を有すると定義される。スキンケア組成物は、上記で定義された色の安定性の他に、スキンケア組成物の安定性は、さらに物理的安定性（例えば、粘度、匂い、外観、テクスチャーなど）および化学的安定性を含みうるがこれらに限定されない。 The skin care composition is stable and may cause no or only slight irritation (i.e., no or only slight tolerable skin irritation) when applied to the skin to treat skin redness. Skin care compositions can be used to treat the root as well as the resulting symptoms of most skin redness symptoms, thereby leading to improved patient compliance. It also has added anti-inflammatory properties for long-term symptom relief. As applied to the compositions of the present invention, the term "stable" means at least When stored for one month, a skin care composition is defined as having the same color when placed on a flat, inert surface (i.e., when removed from its container). In addition to color stability as defined above, the stability of skin care compositions further includes physical stability (e.g., viscosity, odor, appearance, texture, etc.) and chemical stability. However, it is not limited to these.
この新スキンケア組成物は、前述の比率において連続プロセスまたはバッチプロセスを含む様々な方法で作製することができる。非限定的な一例において、ラウレス－４、ココナッツオイルおよびホホバ油を１つの器で共に加熱するとともに、熱した蒸留水、噴霧乾燥アロエベラ粉末グリチルリチン酸二カリウム、フェノキシエタノールおよびサリチロイルフィトスフィンゴシンを別の器で、共に加熱およびせん断混合する。これら２つの混合物が６０－９０℃であるときに、２つの混合物を高速スイープ混合法を使用して混ぜ合わせる。この混合物を１５－２０℃だけ冷却し、増粘剤、すなわちポリアクリルアミド、Ｃ１４－Ｃ１４イソパラフィンおよびラウレス－７を混合物に加え、約５－１５分間よく混合する。次に、ブチレングリコールを混合物に加え、よく混合する。混合物をもう１０－２０℃だけさらに冷却する。アスコルビルリン酸ナトリウムを除く残りの成分を冷却された混合物に加える。続いて、さらに５－１５分間よく混合する。最後に、アスコルビルリン酸ナトリウム（または蒸留水に事前に混合されたアスコルビルリン酸ナトリウムの溶液）をその溶液に加え、さらに５－１５分よく混合する。次に、得られた組成物を、目に見える残留物が残らないように、濾紙および／またはメンブランフィルターを使用して濾過することができる。 This new skin care composition can be made in a variety of ways including continuous or batch processes at the aforementioned ratios. In one non-limiting example, laureth-4, coconut oil, and jojoba oil are heated together in one vessel while heated distilled water, spray-dried aloe vera powder, dipotassium glycyrrhizinate, phenoxyethanol, and salicyloylphytosphingosine are heated in another. Heat and shear mix together in a vessel. When these two mixtures are at 60-90° C., mix the two mixtures using a high speed sweep mixing method. The mixture is cooled by 15-20° C. and the thickeners, namely polyacrylamide, C14-C14 isoparaffin and laureth-7, are added to the mixture and mixed well for about 5-15 minutes. Next, add butylene glycol to the mixture and mix well. The mixture is further cooled by another 10-20°C. Add the remaining ingredients except sodium ascorbyl phosphate to the cooled mixture. Then mix well for an additional 5-15 minutes. Finally, add sodium ascorbyl phosphate (or a solution of sodium ascorbyl phosphate premixed in distilled water) to the solution and mix well for an additional 5-15 minutes. The resulting composition can then be filtered using filter paper and/or membrane filters so that no visible residue remains.
スキンケア組成物は当技術分野で知られている任意の手段によって投与することができる。好ましくは、組成物は局所製剤として処方される。
一実施形態によれば、本発明は、赤く、炎症を起こした皮膚を治療する方法である。その方法は、有効量の本発明のスキンケア組成物を必要に応じて、皮膚発赤に苦しむ人の顔、首、および任意の患部に局所的に塗布することを含む。有効量は、一般的に、少量のスキンケア組成物を含む。スキンケア組成物は、患部またはその周辺、特に顔の皮膚に軽く擦り込まれる場合がある。一実施形態において、本方法は、組成物を有限の時間にわたって皮膚に留まらせておくことを含む。ある実施形態において、スキンケア組成物は、皮膚に留まらせておいてよく、洗い流す必要がない。最適な効果のために、スキンケア組成物は３０－９０日間の、および好ましくは少なくとも６０日の、毎日のスキンケア療法の一部として使用され得る。１つ以上の実施形態において、最大の効果および結果のために、使用者は、組成物を患部に１日複数回、例えば１日２－３回塗布してもよい。交替で、必要に応じてスキンケア組成物が塗布されてもよい。スキンケア組成物は、炎症を起こした皮膚の鎮静を促進し、皮膚に潤いを与え、発赤および炎症の軽減を引き起こす。スキンケア組成物は、塗布後すぐに赤く炎症を起こした肌を落ち着かせるように働くことができる。
Skin care compositions can be administered by any means known in the art. Preferably, the composition is formulated as a topical formulation.
According to one embodiment, the invention is a method of treating red, irritated skin. The method comprises applying an effective amount of the skin care composition of the present invention topically to the face, neck, and any affected areas of a person suffering from skin redness, as needed. An effective amount generally includes a small amount of the skin care composition. Skin care compositions may be rubbed lightly into the skin at or around the affected area, particularly on the face. In one embodiment, the method includes leaving the composition on the skin for a finite amount of time. In some embodiments, the skin care composition may be left on the skin and does not need to be washed off. For optimal effectiveness, the skin care compositions may be used as part of a daily skin care regimen for 30-90 days, and preferably at least 60 days. In one or more embodiments, for maximum effectiveness and results, the user may apply the composition to the affected area multiple times per day, such as 2-3 times per day. Alternately, skin care compositions may be applied as needed. The skin care composition helps soothe irritated skin, moisturizes the skin, and causes a reduction in redness and inflammation. The skin care composition can work to soothe red, irritated skin immediately after application.
目または目の周囲の領域へのスキンケア組成物の塗布を避けることは重要である。本方法は、さらに、薬剤が残っている指／指先で目領域に触れないようにするために、使用者に塗布後に手を洗うように指示することを含む。使用者は、本組成物を塗布するとき保護手袋を着用し、本製品が目に広がることを避けるために鏡を使用することを推奨されてもよい。ある実施形態において、本方法はさらに、（指を使用する代わりに、または加えて）適切な塗布具を使用してスキンケア組成物を塗布することを含む。適切な塗布具を含みうる。適切な塗布具は、パッド、ブラシ、綿棒、スポンジ、パフ、ロールオン式の塗布具、および他のそのような用具を含みうる。 It is important to avoid applying skin care compositions to the eyes or the area around the eyes. The method further includes instructing the user to wash their hands after application to avoid touching the eye area with fingers/fingertips that have residual medication. Users may be advised to wear protective gloves when applying the composition and use a mirror to avoid spreading the product to the eyes. In certain embodiments, the method further includes applying the skin care composition using a suitable applicator (instead of or in addition to using fingers). Appropriate applicators may be included. Suitable applicators may include pads, brushes, cotton swabs, sponges, puffs, roll-on applicators, and other such devices.
ある実施形態において、本方法はさらに、塗布（または再塗布）の前に患部を予備洗浄（または洗浄）することを含む。予備洗浄は、穏やかな、毛穴を詰まらせないクレンザーを使用することを含む場合がある。少量のクレンザーは、目領域を避けて、濡れた肌に擦り込まれ得る。その後、皮膚を完全にすすぎ、軽くたたいて乾かす。ある実施形態において、クレンザーは、水、ラウリン酸ＰＥＧ－８０ソルビタン、トリデセス硫酸ナトリウム、コカミドプロピルヒドロキシスルタイン、ジステアリン酸ＰＥＧ－１５０、ラウロアンホ二酢酸ナトリウム、ラウレス－１３カルボン酸ナトリウム、キサンタンガム、ＰＥＧ－１５ココポリアミン、塩化ナトリウム、フェノキシエタノール、およびソルビン酸カリウムを含む組成物を含みうる。 In certain embodiments, the method further includes pre-cleaning (or cleaning) the affected area prior to application (or reapplication). Pre-cleaning may include using a gentle, non-pore-clogging cleanser. A small amount of cleanser can be rubbed into wet skin, avoiding the eye area. Then rinse the skin thoroughly and pat dry. In certain embodiments, the cleanser comprises water, PEG-80 sorbitan laurate, sodium trideceth sulfate, cocamidopropyl hydroxysultaine, PEG-150 distearate, sodium lauroamphodiacetate, sodium laureth-13 carboxylate, xanthan gum, PEG- 15 cocopolyamine, sodium chloride, phenoxyethanol, and potassium sorbate.
さらに別の実施形態において、皮膚の発赤および炎症の治療または改善に使用される本発明のスキンケア組成物は、キットに含まれ得る。キットは容器を含むことができる。容器は、ボトル、ディスペンサー、加圧容器、金属チューブ、プラスチックチューブ、または組成物を保持可能な他のタイプの容器からなる群から選択することができる。キットおよび／または容器は、その表面に製品の証印（ｐｒｏｄｕｃｔ ｉｎｄｉｃｉａ）を含み得る。証印は、例えば、単語、熟語、略語、絵、または記号であり得る。 In yet another embodiment, skin care compositions of the invention used to treat or ameliorate skin redness and inflammation can be included in a kit. The kit can include a container. The container can be selected from the group consisting of bottles, dispensers, pressurized containers, metal tubes, plastic tubes, or other types of containers capable of holding the composition. The kit and/or container may include product indicia on its surface. An indicia can be, for example, a word, phrase, abbreviation, picture, or symbol.
スキンケア組成物はローション、クリーム、セラム、ジェル、スティック、スプレー、軟膏、液体洗浄液、泡、およびムースからなる群から選択される形態である。したがって、容器は、上記の形態のうちのいずれかで所定量の組成物を分注するように構成される。容器は、スプレー機構、ポンプ機構、または圧搾機構を有し得る。当業者は、キットが本発明のスキンケア組成物の塗布、使用および保管のための使用説明書もまた含み得ることを認識するであろう。 The skin care composition is in a form selected from the group consisting of lotions, creams, serums, gels, sticks, sprays, ointments, liquid washes, foams, and mousses. Accordingly, the container is configured to dispense a predetermined amount of the composition in any of the forms described above. The container may have a spray, pump, or squeeze mechanism. Those skilled in the art will recognize that the kit may also include instructions for applying, using and storing the skin care compositions of the present invention.
ある実施形態において、キットはさらに、適切な塗布具を含みうる。塗布具は、パッド、ブラシ、綿棒、スポンジ、パフおよびロールオン式の塗布具からなる群から選択されてもよい。キットには、また、１つ以上の保護手袋も含まれ得る。 In certain embodiments, the kit may further include a suitable applicator. The applicator may be selected from the group consisting of pads, brushes, cotton swabs, sponges, puffs and roll-on applicators. The kit may also include one or more protective gloves.
ある別の実施形態において、キットは、本発明の局所スキンケア組成物を含む第１の容器と、第２の容器とを含んでもよい。第２の容器は、本明細書に記載される所定の量の毛穴を詰まらせないクレンザーを保持および分注するように作られうる。 In certain other embodiments, a kit may include a first container containing a topical skin care composition of the invention and a second container. The second container can be configured to hold and dispense a predetermined amount of the non-pore-clogging cleanser described herein.
ある実施形態において、キットは、本発明の局所スキンケア組成物を収容する第１の容器と、まぶた洗浄組成物を保持および分注するための別の容器とを含んでもよい。まぶた洗浄組成物は、（ａ）少なくとも７つの菌株を実質的に除去する抗菌剤の混合物であって、当該混合物は、ポリアミノプロピルビグアニド、１，２－グリコール、および、スフィンゴイド脂質を含み、そのスフィンゴイド脂質はサリチロイルフィトスフィンゴシンである；（ｂ）まぶた洗浄組成物を５．５と７．５との間のｐＨに維持する混合された界面活性剤溶液であって、その混合された界面活性剤溶液は、起泡力を有する；（ｃ）泡安定剤；および（ｄ）保湿剤を備え得る。さらに別の実施形態において、キットは、本発明の局所スキンケア組成物を収容する第１の容器と、１つ以上の事前に湿らされた単回使用クレンジングパッドとを含み得る。パッドは、まぶた洗浄組成物を事前に染み込ませることができる。さらに別の実施形態において、キットは、本発明の局所スキンケア組成物を収容する第１の容器と、まぶたクレンジングおよびまぶた洗浄組成物または局所スキンケア組成物を受け取るための１つ以上のパッドを含む第２の容器とを含み得る。パッドは、けば立ちのない織物材料、すなわち、レーヨンまたはまぶた洗浄組成物または局所スキンケア組成物を受け取ることができる別の適切な材料などの適切な織物を含むことができる。パッドは単回使用使い捨てパッドでもよい。一実施形態において、１つ以上のパッドは密封可能な容器に含まれてもよい。一態様において、密封可能な容器は、箱または包装を備えてよい。包装は、プラスチックまたは金属箔材料を含む任意の適切な材料で作られる場合がある。 In certain embodiments, the kit may include a first container containing the topical skin care composition of the invention and another container for holding and dispensing the eyelid cleansing composition. The eyelid cleansing composition comprises (a) a mixture of antimicrobial agents that substantially eliminates at least seven bacterial strains, the mixture comprising polyaminopropyl biguanide, 1,2-glycol, and a sphingoid lipid; The sphingoid lipid is salicyloyl phytosphingosine; (b) a mixed surfactant solution that maintains the eyelid cleansing composition at a pH between 5.5 and 7.5, comprising: The surfactant solution has foaming properties; (c) a foam stabilizer; and (d) a humectant. In yet another embodiment, a kit may include a first container containing a topical skin care composition of the invention and one or more pre-moistened single-use cleansing pads. The pad can be pre-soaked with an eyelid cleaning composition. In yet another embodiment, the kit includes a first container containing a topical skin care composition of the invention and one or more pads for receiving an eyelid cleansing and washing composition or a topical skin care composition. 2 containers. The pad may comprise a suitable textile material, such as a lint-free textile material, ie, rayon, or another suitable material capable of receiving an eyelid cleaning composition or topical skin care composition. The pad may be a single use disposable pad. In one embodiment, one or more pads may be contained in a sealable container. In one embodiment, the sealable container may comprise a box or packaging. The packaging may be made of any suitable material including plastic or metal foil materials.
本発明の範囲または精神から逸脱することなく、本発明において様々な変更および変形を行うことができることは、当業者には明らかであろう。本発明の他の実施形態は、本明細書の考慮および本明細書に開示された本発明の実施から、当業者には明らかであろう。本明細書および実施例は、単なる例示とみなされることが意図されている。 It will be apparent to those skilled in the art that various changes and modifications can be made to the present invention without departing from the scope or spirit of the invention. Other embodiments of the invention will be apparent to those skilled in the art from consideration of this specification and practice of the invention disclosed herein. It is intended that the specification and examples be considered as illustrative only.
Claims (4)
Cream according to claim 1, wherein the pH of the cream is between 4.5 and 6.0.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862640848P | 2018-03-09 | 2018-03-09 | |
| US62/640,848 | 2018-03-09 | ||
| JP2020546974A JP2021515021A (en) | 2018-03-09 | 2019-03-07 | Topical skin care composition |
| PCT/US2019/021142 WO2019173584A1 (en) | 2018-03-09 | 2019-03-07 | Topical skin care compositions |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020546974A Division JP2021515021A (en) | 2018-03-09 | 2019-03-07 | Topical skin care composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2023155497A true JP2023155497A (en) | 2023-10-20 |
Family
ID=67842864
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020546974A Pending JP2021515021A (en) | 2018-03-09 | 2019-03-07 | Topical skin care composition |
| JP2023142791A Pending JP2023155497A (en) | 2018-03-09 | 2023-09-04 | topical skin care compositions |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020546974A Pending JP2021515021A (en) | 2018-03-09 | 2019-03-07 | Topical skin care composition |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US10576048B2 (en) |
| EP (1) | EP3761952A4 (en) |
| JP (2) | JP2021515021A (en) |
| KR (1) | KR20200131850A (en) |
| CN (1) | CN111836614A (en) |
| AR (1) | AR114376A1 (en) |
| AU (1) | AU2019230097B2 (en) |
| CA (1) | CA3093428C (en) |
| GB (1) | GB2586731B (en) |
| MX (1) | MX2020009161A (en) |
| MY (1) | MY195546A (en) |
| NZ (1) | NZ768571A (en) |
| SG (1) | SG11202008507PA (en) |
| TW (1) | TW201940187A (en) |
| UY (1) | UY38139A (en) |
| WO (1) | WO2019173584A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102592150B1 (en) * | 2020-07-09 | 2023-10-20 | 크로다코리아 주식회사 | Novel sphingolipid containing salicylic acid derivatives and composition comprising the same |
| US20220110996A1 (en) * | 2020-10-12 | 2022-04-14 | Wanda Lewis | Moisturizing composition |
| CN113398020B (en) * | 2021-05-28 | 2022-06-17 | 植物医生(广东)生物科技有限公司 | Composition with functions of refining pores and brightening skin color and application thereof |
| WO2023114855A1 (en) * | 2021-12-17 | 2023-06-22 | Ocusoft, Inc. | Cleansing, moisturizing and non-irritating topical compositions |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6472432B1 (en) * | 1997-11-17 | 2002-10-29 | Nicholas V. Perricone | Treatment of rosacea using lipoic acid |
| US6680062B2 (en) * | 2001-10-05 | 2004-01-20 | Color Access, Inc. | Anti-irritating rosacea treatment |
| AU2003205278B2 (en) * | 2002-01-18 | 2008-08-07 | Psivida Us Inc. | Polymeric gel system for the controlled delivery of codrugs |
| FR2868702B1 (en) * | 2004-04-09 | 2006-12-22 | Negma Lerads Soc Par Actions S | USE OF A SPHINGOID BASE ASSOCIATED WITH NICOTINIC ACID OR AN AMIDE OF NICOTINIC ACID AS DEPIGMENTING AGENT |
| FR2870125B1 (en) * | 2004-05-12 | 2010-03-26 | Dermaconcept Jmc | FORMULATION OF THE SPOT-ON TYPE USEFUL IN COSMETOLOGY AND DERMATOLOGY |
| JP5570696B2 (en) | 2004-06-03 | 2014-08-13 | ブラウン、ジェイ．スティーブン | Disinfecting composition and method for producing the same |
| ES2298885T3 (en) * | 2005-06-30 | 2008-05-16 | Evonik Goldschmidt Gmbh | USE OF A SALICILOIL-SPHINGOID BASE FOR THE TREATMENT OR PREVENTION OF CELLULITIS. |
| DE102005057593A1 (en) | 2005-07-08 | 2007-01-11 | Schwan-Stabilo Cosmetics Gmbh & Co. Kg | Preparation, in particular cosmetic preparation, and their preparation and use |
| WO2009046116A1 (en) * | 2007-10-01 | 2009-04-09 | Dennis Gross | Skin care products containing multiple enhancers |
| DE102007049612A1 (en) * | 2007-10-17 | 2009-06-10 | Evonik Goldschmidt Gmbh | Bioactive composition for cosmetic applications |
| US8481006B2 (en) * | 2008-04-25 | 2013-07-09 | New Sunshine, Llc | Melt formula |
| WO2013149323A1 (en) * | 2012-04-02 | 2013-10-10 | Ntegrity | Natural products for skin care |
| JP6046929B2 (en) | 2012-06-25 | 2016-12-21 | 株式会社キーエンス | Optical measuring device |
| EP2740484A1 (en) * | 2012-12-05 | 2014-06-11 | Lipotec, S.A. | Compounds useful in the treatment and/or care of the skin, hair and/or muccous membranes and their cosmetic or pharmaceutical compositions |
| US20140271509A1 (en) * | 2013-03-15 | 2014-09-18 | Inderma, Inc. | Compositions for Skin Lightening and/or Brightening |
| CN103202780A (en) * | 2013-04-16 | 2013-07-17 | 纪艺琼 | Nano essence for cosmetic and preparation method thereof |
| JP6559914B2 (en) * | 2016-04-04 | 2019-08-14 | オキュソフト インコーポレイテッドＯＣｕＳＯＦＴ，Ｉｎｃ． | Composition, kit and method for maintaining eyelid hygiene |
| CN106176274B (en) * | 2016-08-26 | 2020-04-10 | 深圳市维琪医药研发有限公司 | Polypeptide composition with anti-allergy effect |
| EP3175838A1 (en) * | 2017-03-16 | 2017-06-07 | Evonik Degussa GmbH | Foamed, oil-in-water emulsion containing formulations containing at least one co-surfactant |
-
2019
- 2019-03-07 MX MX2020009161A patent/MX2020009161A/en unknown
- 2019-03-07 TW TW108107615A patent/TW201940187A/en unknown
- 2019-03-07 SG SG11202008507PA patent/SG11202008507PA/en unknown
- 2019-03-07 EP EP19765127.6A patent/EP3761952A4/en active Pending
- 2019-03-07 CN CN201980018079.1A patent/CN111836614A/en active Pending
- 2019-03-07 GB GB2015640.2A patent/GB2586731B/en active Active
- 2019-03-07 MY MYPI2020004519A patent/MY195546A/en unknown
- 2019-03-07 US US16/295,617 patent/US10576048B2/en active Active
- 2019-03-07 KR KR1020207028930A patent/KR20200131850A/en not_active Application Discontinuation
- 2019-03-07 AR ARP190100562A patent/AR114376A1/en unknown
- 2019-03-07 WO PCT/US2019/021142 patent/WO2019173584A1/en active Application Filing
- 2019-03-07 JP JP2020546974A patent/JP2021515021A/en active Pending
- 2019-03-07 CA CA3093428A patent/CA3093428C/en active Active
- 2019-03-07 UY UY38139A patent/UY38139A/en unknown
- 2019-03-07 AU AU2019230097A patent/AU2019230097B2/en active Active
- 2019-03-07 NZ NZ768571A patent/NZ768571A/en unknown
-
2020
- 2020-01-31 US US16/778,337 patent/US10993922B2/en active Active
-
2023
- 2023-09-04 JP JP2023142791A patent/JP2023155497A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3761952A1 (en) | 2021-01-13 |
| SG11202008507PA (en) | 2020-10-29 |
| CN111836614A (en) | 2020-10-27 |
| AU2019230097B2 (en) | 2021-10-28 |
| US10993922B2 (en) | 2021-05-04 |
| US10576048B2 (en) | 2020-03-03 |
| EP3761952A4 (en) | 2021-12-15 |
| GB2586731B (en) | 2023-04-19 |
| CA3093428A1 (en) | 2019-09-12 |
| UY38139A (en) | 2019-08-30 |
| MY195546A (en) | 2023-01-31 |
| US20190274977A1 (en) | 2019-09-12 |
| TW201940187A (en) | 2019-10-16 |
| KR20200131850A (en) | 2020-11-24 |
| MX2020009161A (en) | 2022-10-13 |
| GB2586731A (en) | 2021-03-03 |
| US20200163909A1 (en) | 2020-05-28 |
| JP2021515021A (en) | 2021-06-17 |
| AU2019230097A1 (en) | 2020-10-22 |
| AR114376A1 (en) | 2020-08-26 |
| NZ768571A (en) | 2024-01-26 |
| CA3093428C (en) | 2023-07-11 |
| WO2019173584A1 (en) | 2019-09-12 |
| GB202015640D0 (en) | 2020-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10993922B2 (en) | Topical skin care compositions | |
| CA2760591C (en) | Cleanser compositions and methods for using the same | |
| KR101420599B1 (en) | Compositions containing anti-acne agents and the use thereof | |
| US20070292459A1 (en) | Halloysite microtubule processes, structures, and compositions | |
| MXPA97005954A (en) | Formulations and methods to reduce irritation of the p | |
| CN104812398A (en) | Topical compositions and methods of use | |
| CN108186679A (en) | A kind of acne-removing composition | |
| US20060222689A1 (en) | Skin care compositions and methods | |
| JP2010522757A (en) | Treatment of mammalian skin with skin emollient fungicide | |
| US20140287064A1 (en) | Compositions for improving the appearance and/or treating fungal infections of nails, mucus membranes and the integument | |
| RU2295951C1 (en) | Composition for face and eyelids skin care | |
| RU2394557C1 (en) | Set of means for acne treatment | |
| JP2022534485A (en) | Skin therapeutic compositions and preservative systems | |
| CN111936130A (en) | Topical formulations comprising strontium and methylsulfonylmethane (MSM) and methods of treatment | |
| US20070207115A1 (en) | Tea Tree Oil and Benzoyl Peroxide Acne Treatment | |
| JP3479048B2 (en) | Cosmetics and non-woven fabric impregnated cosmetics | |
| CA3005010A1 (en) | Skin care composition | |
| US11865138B2 (en) | Methods and compositions for therapeutic skin treatments in dermatological procedures affecting skin's barrier | |
| US20160184220A1 (en) | Method for the Prevention and Treatment of Acne | |
| JP2007016025A (en) | Topical composition for skin and method | |
| DE202006019185U1 (en) | Moisture aqueous sea buckthorn skin care preparation, useful to nourish and clean skin, which is damaged by cancer therapy, comprises waxes and fats, vitamins, plant hydrolates, moisturizing substances, material mixtures, and pH-regulators | |
| WO2024042476A1 (en) | Methods of providing a cooling sensation to skin afflicted with eczema | |
| WO2024042475A1 (en) | Methods of improving the appearance of skin afflicted with eczema | |
| WO2024042474A1 (en) | Compositions suitable for use on skin afflicted with eczema | |
| Somwanshi et al. | Cosmetic Science |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230904 |